ischemic cerebrovascular disease
Conditions
Interventions
trial group:YiqiHuoxueHuatanTongluo formula
control group:placebo
Sponsors
China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1 Patients undergoing stent therapy within 14 days because of symptomatic severe vertebral artery stenosis (=70% stenosis as confirmed by DSA) had postoperative residual stenosis <20%, without serious perioperative complications 2 Patients with qi deficiency and blood stasis and phlegm 3 Age is 30-80 years, with no pregnancy planner within 6 months 4 Patients and/or family members signed the informed consent
Exclusion criteria
Exclusion criteria: 1 Patients with severe heart, liver and kidney diseases, coagulation dysfunction and malignant tumors 2 People with a history of allergy or serious adverse reactions to the test drug and its accessories 3 Patients with gastrointestinal ulcer cannot be tolerated with double antiplatelet therapy 4 Pregnancy, breastfeeding women or pregnancy plan recently 5 Unable to take the medicine according to the prescribed dose and course of treatment 6 Use of other TCM for the treatment of cerebrovascular diseases 7 Patients who have participated in other drug clinical trials within 3 months 8 Other circumstances not unsuitable to participate in this trial by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TCM syndrome score;MMSE score;NIHSS score;ADL score;late lumen loss;Cerebral ischemic event;restenosis;thrombelastogram;SSQOL score; | — |
Countries
China
Contacts
Public ContactTONGChenguang
Outcome results
None listed